Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The options were granted as an inducement material to three employees entering into employment with Astria in accordance with ...
Business Wire4d
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
Investing4d
Astria Therapeutics gains orphan drug status in EU for HAE treatment
BOSTON - Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company, has recently been granted Orphan Medicinal Product Designation (OMPD) by the European Commission for its drug ...
Business Insider23d
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Santhera Pharmaceuticals Holding (OtherSPHDF) and Agios Pharma (AGIO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Astria Therapeutics (ATXS – Research Report), Santhera Pharmaceuticals Holding (SPHDF ...
Morningstar20d
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that navenibart (STAR-0215 ...
ETF Daily News8d
Cubist Systematic Strategies LLC Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)
Astria Therapeutics, Inc. has a one year low of $4.26 and a one year high of $16.90. Astria Therapeutics ( NASDAQ:ATXS – Get Free Report ) last announced its quarterly earnings data on Monday ...
Business Insider24d
Evercore ISI Sticks to Their Buy Rating for Astria Therapeutics (ATXS)
In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a price target of $25.00. The company’s shares closed ...
Investing21d
Astria Therapeutics shares hold with Buy rating on OX40 program optimism
On Friday, H.C. Wainwright maintained a Buy rating for Astria Therapeutics (NASDAQ:ATXS), with a steadfast price target of $16.00. The firm's attention was drawn to recent developments earlier in the ...
Morningstar17d
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing3d
Astria Therapeutics gains orphan drug status in EU for HAE treatment
BOSTON - Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company, has recently been granted Orphan Medicinal Product Designation (OMPD) by the European Commission for its drug navenibart, ...
Business Wire17d
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock ...